Scarica l'app Stockscreener
6.01
1.15%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXST Giù?
Forum
Previsione
Precedente Chiudi:
$6.08
Aprire:
$6.08
Volume 24 ore:
540.86K
Relative Volume:
0.51
Capitalizzazione di mercato:
$248.79M
Reddito:
$134.48M
Utile/perdita netta:
$-38.94M
Rapporto P/E:
-6.3038
EPS:
-0.9534
Flusso di cassa netto:
$-19.34M
1 W Prestazione:
+15.80%
1M Prestazione:
+24.69%
6M Prestazione:
-30.84%
1 anno Prestazione:
-22.75%
Intervallo 1D:
$5.86
$6.115
Intervallo di 1 settimana:
$5.25
$6.225
Portata 52W:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Nome
Rxsight Inc
Settore
Industria
Telefono
949-521-7822
Indirizzo
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
6.01 | 233.48M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | William Blair | Mkt Perform |
| 2025-07-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Downgrade | Jefferies | Buy → Hold |
| 2025-07-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Iniziato | Piper Sandler | Neutral |
| 2025-04-09 | Downgrade | UBS | Buy → Neutral |
| 2025-04-04 | Downgrade | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-12-20 | Downgrade | Stifel | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-10-29 | Iniziato | Jefferies | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-05-07 | Reiterato | BTIG Research | Buy |
| 2023-12-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Iniziato | Morgan Stanley | Overweight |
| 2023-04-13 | Iniziato | Oppenheimer | Outperform |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Iniziato | Needham | Buy |
Mostra tutto
Rxsight Inc Borsa (RXST) Ultime notizie
UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating - marketscreener.com
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - hrtoday.in
Midday Stock Roundup: Rivian Automotive Up on Piper Sandler Upgrade - Orange County Business Journal
Rxsight Inc (RXST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles - Glance by Eyes On Eyecare
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rxsight Inc (RXST) Valuation: PE, PB & Fair Value Analysis - TradingKey
RxSight grants new CEO Aziz Mottiwala stock options for 571,286 shares at $5.19 each - Bitget
RxSight grants inducement stock options and RSU... - Pluang
New RxSight CEO's 2.31M RSU award vests over three years - Stock Titan
Rxsight Inc (RXST) Income Statement - TradingKey
Levi & Korsinsky Notifies RxSight, Inc. (RXST) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline - The National Law Review
RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut - Yahoo Finance
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Form 4 Rxsight Inc For: 24 July By Investing.com - Investing.com Nigeria
RxSight, Inc. (RXST) awards CEO 2,312,138 RSUs and 571,286 options - Stock Titan
Lost Money on RxSight, Inc. (RXST)? Urged to Join Class Action Before September 22, 2025Contact Levi & Korsinsky - The National Law Review
RXST|Rxsight Inc|Price:5.205|Chg%:-0.165 - TradingKey
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RxSight, Inc. (RXST) Stock Analysis: Can this Medical Device Innovator Surge with a 56.96% Potential Upside? - DirectorsTalk Interviews
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RXST|Rxsight Inc|Price:5.155|Chg%:-0.215 - TradingKey
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RxSight Lands Tarsus Commercial Leader as CEO - Orange County Business Journal
RxSight (RXST) surges 6.1%: Is this an indication of further gains? - MSN
RxSight appoints new CEO - MSN
RXST stock holds as RxSight advances its light-adjustable lens business - Ad-hoc-news.de
BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight - Stock Titan
BTIG Maintains RxSight(RXST.US) With Hold Rating, Announces Target Price $5.25 - Moomoo
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BTIG Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $5.25 - Moomoo
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO - VisionMonday.com
RxSight names Aziz Mottiwala as new CEO effective July 20 - Investing.com UK
RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com - Investing.com Australia
RxSIGHT announces significant leadership appointments - Bitget
Ron Kurtz Steps Down as RxSight CEO - Orange County Business Journal
RxSight Names Aziz Mottiwala as CEO - Moomoo
RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package - Stock Titan
RxSight Announces Appointments of Aziz Mottiwala as Chief - GlobeNewswire
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology - Zacks Investment Research
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - TradingView
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
Rxsight Inc Azioni (RXST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rxsight Inc Azioni (RXST) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
1.04%
11.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):